Shaw W, McHan J
Ther Drug Monit. 1981;3(2):185-91. doi: 10.1097/00007691-198102000-00012.
We have adapted commercial immunoassay (EMIT) procedures for dilantin, phenobarbital, theophylline, carbamazepine, tobramycin, disopyramide, quinidine, procainamide, N-acetyl procainamide, and mysoline to two different centrifugal analyzers (Centrifichem and Multistat) using maximum dilutions of reagents to reduce reagent costs to approximately one-tenth of that incurred using the manufacturer's protocol. This savings due to the dilutions of reagents was primarily because of the ability to prolong the reaction time to achieve acceptably large absorbance changes over the absorbance measurement period. Correlation coefficients between values for drugs analyzed by these modified EMIT protocols and values obtained by other methods ranged from 0.927 to 0.994. Within-run precision and recovery values for these drugs were also entirely acceptable. We found that premature mixing of reagents in the rotors of the Multistat system and variable delivery of reagent in the Centrifichem 400 system were both caused by the surfactant in the EMIT buffer. The former problem is being resolved by the manufacturer; the latter problem was resolved by siliconizing the reagent pipet tips.
我们已将用于苯妥英、苯巴比妥、茶碱、卡马西平、妥布霉素、丙吡胺、奎尼丁、普鲁卡因胺、N-乙酰普鲁卡因胺和乙琥胺的商业免疫分析（EMIT）程序，适配到两种不同的离心分析仪（Centrifichem和Multistat）上，通过使用试剂的最大稀释度，将试剂成本降低至约为按照制造商方案所产生成本的十分之一。由于试剂稀释而节省成本，主要是因为能够延长反应时间，以便在吸光度测量期间实现可接受的较大吸光度变化。通过这些改良的EMIT方案分析的药物值与通过其他方法获得的值之间的相关系数在0.927至0.994之间。这些药物的批内精密度和回收率值也完全可以接受。我们发现，Multistat系统转子中试剂的过早混合以及Centrifichem 400系统中试剂的可变输送，均由EMIT缓冲液中的表面活性剂引起。前一个问题正由制造商解决；后一个问题通过对试剂移液管尖端进行硅化处理得以解决。
